Does sequencing of therapy affect outcomes of treatment with sipuleucel-T + ADT in high-risk disease?

We still have very little knowledge about whether early prostate cancer immunotherapy with sipuleucel-T (Provenge) or other forms of immunotherapy might be beneficial in the management of patients with high-risk prostate cancer. … READ MORE …

Intermittent vs. continuous ADT: the results of the ICELAND trial

The results of early, large, randomized trials of intermittent (IADT) vs. continuous androgen deprivation therapy (CADT) have provided conflicting results. However, one of the flaws in early trials was the failure to ensure that men enrolled into these trials all actually had an optimal initial response to androgen deprivation (ADT). … READ MORE …

The EMBARK trial in men with progressive but non-metastatic prostate cancer

We apparently managed to miss providing readers with information about initiation of what may be a game-changing, randomized, Phase III, trial in the treatment of progressive prostate cancer. … READ MORE …

The risk for cardiovascular events among prostate cancer patients on ADT (again)

As our regular readers will be well aware, the topic of risk for cardiovascular disease among prostate cancer patients being treated with any form of androgen deprivation therapy (ADT, also known as “hormone” therapy) comes up on a regular basis. … READ MORE …

ADT, patient survival, and serum testosterone levels after initiation of treatment

Over the years there have been multiple debates about whether different types of androgen deprivation therapy (ADT) really do or don’t extend the survival of men with advanced prostate cancer of differing types and whether the degree to which ADT initially suppresses serum testosterone levels affects that survival. … READ MORE …

Androgen deprivation therapy and escalated dosing in radiation therapy

Several recent studies shed light on the optimal use of androgen deprivation therapy (ADT) used in conjunction with radiation therapy (RT), including new learnings about timing of ADT, RT dose, and their use in various risk categories. … READ MORE …

What is “bipolar” androgen deprivation therapy?

A report just published in Science Translational Medicine describes a new mode of treatment for men with metastatic, castration-resistant prostate cancer (mCRPC) which the authors have called “bipolar” androgen deprivation therapy (BAT). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,261 other followers